Published in Immunology on February 01, 1984
A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol (1973) 45.44
Separation of mouse spleen cells by passage through columns of sephadex G-10. J Immunol Methods (1974) 7.19
The role of macrophages in the generation of T-helper cells. II. The genetic control of the macrophage-T-cell interaction for helper cell induction with soluble antigens. J Exp Med (1975) 5.48
Two distinct types of helper T cells involved in the secondary antibody response: independent and synergistic effects of Ia- and Ia+ helper T cells. J Exp Med (1978) 3.80
Immunogenicity of trinitrophenyl-hemocyanin: production of primary and secondary anti-hapten precipitins. J Immunol (1966) 3.56
Regulation by the H-2 gene complex of macrophage-lymphoid cell interactions in secondary antibody responses in vitro. J Exp Med (1976) 3.10
Cooperative interaction of B lymphocytes with antigen-specific helper T lymphocytes is MHC restricted. Nature (1981) 2.85
Cellular and genetic control of antibody responses. V. Helper T-cell recognition of H-2 determinants on accessory cells but not B cells. J Exp Med (1979) 2.75
Collaboration of allogeneic T and B lymphocytes in the primary antibody response to sheep erythrocytes in vitro. J Exp Med (1975) 2.30
Antigen-specific. I region-restricted interactions in vitro between tumor cell lines and T cell hybridomas. J Immunol (1982) 2.26
Helper T cells recognise antigen and macrophage surface components simultaneously. Nature (1976) 2.18
Allogeneic carrier-specific enhancement of hapten-specific secondary B-cell responses. J Exp Med (1976) 1.87
Clonal induction of helper T cells: conversion of specific signals into nonspecific signals. Int Arch Allergy Appl Immunol (1980) 1.72
The influence of the major histocompatibility complex on the function of T-helper cells in antibody formation. Immunol Rev (1978) 1.64
Conditions determining the generation and expression of T helper cells. Immunol Rev (1977) 1.49
Generation of T helper cells in vitro. IV. F1 T helper cells primed with antigen-pulsed parental macrophages are genetically restricted in their antigen-specific helper activity. J Immunol (1978) 1.48
I region-restricted antigen presentation by B cell-B lymphoma hybridomas. Nature (1982) 1.48
The histocompatibility restrictions on macrophage T-helper cell interaction determine the histocompatibility restrictions on T-helper cell B-cell interaction. J Exp Med (1978) 1.32
Nature of T-cell macrophage interaction in helper-cell induction in vitro. II. Two stages of T-helper-cell differentiation analyzed in irradiation and allophenic chimeras. J Exp Med (1979) 1.20
Studies on the generation and expression of H-2-controlled T helper function in chimeric mice: evidence for two levels of H-2 resitriction. Eur J Immunol (1979) 1.16
Analysis of histocompatibility requirements for proliferative and helper T cell activity. T cell populations depleted of alloreactive cells by negative selection. J Exp Med (1980) 1.14
Cellular and genetic control of antibody responses. VIII. MHC restricted recognition of accessory cells, not B cells, by parent-specific subpopulations of normal F1 T helper cells. J Immunol (1980) 0.98
T cell help mechanisms in the in vitro antibody response: the role of linked and non-linked recognition interactions. Immunology (1984) 0.76
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature (1985) 9.62
"Infectious" transplantation tolerance. Science (1993) 4.98
Reshaping human antibodies for therapy. Nature (1988) 4.82
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells. Infect Immun (1987) 3.87
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med (1987) 3.82
Different roles for L3T4+ and Lyt 2+ T cell subsets in the control of an acute herpes simplex virus infection of the skin and nervous system. J Gen Virol (1987) 3.16
Functional analysis of T lymphocyte subsets in antiviral host defense. J Immunol (1987) 3.11
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia (2010) 2.65
Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet (1988) 2.51
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol (1999) 2.28
Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet (1998) 2.26
Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature (1986) 2.25
IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol (2000) 2.04
Letter: T cell-dependent mediator in the immune response. Nature (1973) 1.94
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 1.93
Induction of classical transplantation tolerance in the adult. J Exp Med (1989) 1.91
The effect on the growth of BP8 ascites tumour in C3H-C57 or C3H mice of "lymphocyte preparations" from C57 mice injected with BP8 cells and Freund's adjuvant. Br J Cancer (1967) 1.88
Limiting dilution analysis of helper T-cell function. Immunology (1975) 1.82
Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood (1983) 1.80
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest (1991) 1.79
Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur J Immunol (1990) 1.79
Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis (1984) 1.78
The CAMPATH-1 antigen (CDw52). Tissue Antigens (1990) 1.78
Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol Rev (1996) 1.77
T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant (1994) 1.76
Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate (1996) 1.73
Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet (1992) 1.72
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet (1999) 1.69
Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation (1999) 1.67
Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum (2001) 1.67
Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM (1996) 1.66
T cell-dependent mediator in the immune response. II. Physical and biological properties. Immunology (1974) 1.65
The influence of the major histocompatibility complex on the function of T-helper cells in antibody formation. Immunol Rev (1978) 1.64
Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med (1988) 1.63
Posttranscriptional regulation of IL-10 gene expression through sequences in the 3'-untranslated region. J Immunol (2000) 1.60
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet (1994) 1.59
In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science (1995) 1.56
Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance. J Immunol (2000) 1.55
Induction of tolerance by monoclonal antibody therapy. Nature (1986) 1.53
Cooperation across the histocompatibility barrier. Nature (1975) 1.51
CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. J Immunol (1999) 1.50
Conditions determining the generation and expression of T helper cells. Immunol Rev (1977) 1.49
Skin allograft rejection by L3/T4+ and Lyt-2+ T cell subsets. Transplantation (1986) 1.49
Antigen-non-specific T-cell factor in B-cell activation. Origin, biological properties and failure to show a relationship to H-2. Immunology (1976) 1.49
Self tolerance is H-2-restricted. Nature (1984) 1.47
Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J (1993) 1.46
T cell suppression in transplantation tolerance through linked recognition. J Immunol (1996) 1.45
Regulation of IL-18 (IFN-gamma-inducing factor) gene expression. J Immunol (1997) 1.44
The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol (1993) 1.44
Radiotherapy-based conditioning is effective immunosuppression for patients undergoing transplantation with T-cell depleted stem cell grafts for severe aplasia. Cytotherapy (2004) 1.42
Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain (1996) 1.40
Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet (1993) 1.40
The role of CD4+ T-cell subsets in determining transplantation rejection or tolerance. Immunol Rev (2001) 1.40
Infectious tolerance. Curr Opin Immunol (1998) 1.39
T cell-dependent mediator in the immune response. III. The role of non-specific factor (NSF) in the in vitro immune response. Immunology (1975) 1.39
Use of Ceprate CD34-positive selection system for depletion of T cells in allogeneic transplantation. Bone Marrow Transplant (1997) 1.39
Amplification of natural regulatory immune mechanisms for transplantation tolerance. Transplantation (1996) 1.39
The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies. Eur J Immunol (1990) 1.39
Regulation of CD40 function by its isoforms generated through alternative splicing. Proc Natl Acad Sci U S A (2001) 1.38
A rapid solid-phase enzyme-linked binding assay for screening monoclonal antibodies to cell surface antigens. J Immunol Methods (1981) 1.38
Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol (1985) 1.37
Identification of macrophages and smooth muscle cells in human atherosclerosis using monoclonal antibodies. J Pathol (1985) 1.34
Do L3T4+ T cells act as effector cells in protection against influenza virus infection. Immunology (1987) 1.33
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest (1996) 1.33
Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med (1986) 1.33
Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med (1990) 1.32
Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet (1984) 1.31
CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur J Immunol (1987) 1.31
Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol Rev (1992) 1.27
A role for CD4+ but not CD8+ T cells in immunity to Schistosoma mansoni induced by 20 krad-irradiated and Ro 11-3128-terminated infections. Immunology (1989) 1.27
Biology-inspired synthesis of compound libraries. Cell Mol Life Sci (2008) 1.26
Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: no requirement for CD8+ T cells or B cells. J Immunol (1998) 1.26
The immunogenicity of chimeric antibodies. J Exp Med (1989) 1.25
Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood (1989) 1.25
Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol (1991) 1.25
S-Acylation and plasma membrane targeting of the farnesylated carboxyl-terminal peptide of N-ras in mammalian fibroblasts. Biochemistry (1997) 1.22
Tolerance to rat monoclonal antibodies. Implications for serotherapy. J Exp Med (1986) 1.21
Removal of T cells from bone marrow for transplantation. Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes. Mol Biol Med (1983) 1.21
Linked suppression of skin graft rejection can operate through indirect recognition. J Immunol (1998) 1.20
Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo. Transplantation (1986) 1.20
Directed differentiation of dendritic cells from mouse embryonic stem cells. Curr Biol (2000) 1.20
T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. Transplantation (1988) 1.18
Influence of the major histocompatibility complex on lymphocyte interactions in antibody formation. Nature (1978) 1.17
Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant (1986) 1.17
Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H. Eye (Lond) (1995) 1.17
Large-scale purification of murine I-Ak and I-Ek antigens and characterization of the purified proteins. Mol Immunol (1983) 1.16
Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur J Immunol (1988) 1.15
Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun (1998) 1.15
A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin Exp Immunol (1996) 1.15
Limiting dilution analysis of cells of the immune system II: What can be learnt? Immunol Today (1984) 1.14
Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol (2000) 1.13
The influence of thymus on the development of MHC restrictions exhibited by T-helper cells. Nature (1979) 1.13
Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant (1994) 1.13
'Paedfusor' pharmacokinetic data set. Br J Anaesth (2005) 1.13
A superior method of tattoo removal using the Q-switched ruby laser. J Dermatol Surg Oncol (1990) 1.12
The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol (2001) 1.11
Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation (1999) 1.10